Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Outstanding (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Shares Outstanding over the past 12 years, most recently at $101.8 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $101.8 million for Q4 2025, up 25.72% from a year ago — trailing twelve months through Dec 2025 was $101.8 million (up 25.72% YoY), and the annual figure for FY2025 was $101.8 million, up 25.72%.
  • Shares Outstanding for Q4 2025 was $101.8 million at Viridian Therapeutics, Inc.\DE, up from $82.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding for VRDN hit a ceiling of $101.8 million in Q4 2025 and a floor of $321334.0 in Q3 2021.
  • Median Shares Outstanding over the past 5 years was $43.6 million (2023), compared with a mean of $49.8 million.
  • Biggest five-year swings in Shares Outstanding: soared 188268.97% in 2023 and later increased 3.85% in 2025.
  • Viridian Therapeutics, Inc.\DE's Shares Outstanding stood at $23.9 million in 2021, then surged by 72.65% to $41.3 million in 2022, then skyrocketed by 30.7% to $54.0 million in 2023, then surged by 50.03% to $81.0 million in 2024, then grew by 25.72% to $101.8 million in 2025.
  • The last three reported values for Shares Outstanding were $101.8 million (Q4 2025), $82.2 million (Q3 2025), and $81.7 million (Q2 2025) per Business Quant data.